N/A
N=43
HFCWO in Hospitalized Asthmatic Children
Bronchial Asthma · Asthma · Status Asthmaticus
Bottom Line
View on ClinicalTrials.gov: NCT00722020 ↗Enrolled (actual)
43
Serious AEs
0.0%
Results posted
Nov 2015
Primary outcome: Primary: The Primary Endpoint Will be Time to Readiness for Discharge. — 1.74; 1.75 days
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- VEST (Device)
- Age
- Pediatric, Adult · 0+ yrs
- Sex
- All
- Sponsor
- Hill-Rom
- Primary completion
- Jun 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Primary Endpoint Will be Time to Readiness for Discharge. |
1.74; 1.75 | — |
| SECONDARY Secondary Endpoint Total Hospital Length of Stay |
2.5; 2.5 | — |
Summary
To determine whether or not high frequency chest wall oscillation (in the form of the VestTM) is superior to regular asthma therapy in the management of children hospitalized with moderate to severe asthma.
Eligibility Criteria
Inclusion Criteria
- Any pediatric patient between the ages of 18 months and 18 years admitted to Winthrop University Hospital's pediatric floor or intensive care unit with a diagnosis of asthma or reactive airway disease
Exclusion Criteria
- Patients with chronic, comorbid respiratory conditions (e.g., cerebral palsy, cystic fibrosis)
- Those who regularly use HFCWO
- Any patient exhibiting an absolute contraindication to HFCWO therapy
- Absolute contraindications to using HFCWO include head and neck injury prior to stabilization, and active hemorrhage with hemodynamic instability
Data sourced from ClinicalTrials.gov (NCT00722020). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.